| Literature DB >> 29880615 |
Fathima Zumla Cader1, Ron C J Schackmann2, Xihao Hu3,4, Kirsty Wienand1, Robert Redd3,4, Bjoern Chapuy1, Jing Ouyang1, Nicole Paul5, Evisa Gjini6, Mikel Lipschitz6, Philippe Armand1, David Wu7, Jonathan R Fromm7, Donna Neuberg3,4, X Shirley Liu3,4, Scott J Rodig6, Margaret A Shipp1.
Abstract
In classical Hodgkin lymphoma (cHL), the host antitumor immune response is ineffective. Hodgkin Reed-Sternberg (HRS) cells have multifaceted mechanisms to evade the immune system, including 9p24.1/CD274(PD-L1)/PDCD1LG2(PD-L2) genetic alterations, overexpression of PD-1 ligands, and associated T-cell exhaustion and additional structural bases of aberrant antigen presentation. The clinical success of PD-1 blockade in cHL suggests that the tumor microenvironment (TME) contains reversibly exhausted T effector cells (Teffs). However, durable responses are observed in patients with β2-microglobulin/major histocompatibility complex (MHC) class I loss on HRS cells, raising the possibility of non-CD8+ T cell-mediated mechanisms of efficacy of PD-1 blockade. These observations highlight the need for a detailed analysis of the cHL TME. Using a customized time-of-flight mass cytometry panel, we simultaneously assessed cell suspensions from diagnostic cHL biopsies and control reactive lymph node/tonsil (RLNT) samples. Precise phenotyping of immune cell subsets revealed salient differences between cHLs and RLNTs. The TME in cHL is CD4+ T-cell rich, with frequent loss of MHC class I expression on HRS cells. In cHLs, we found concomitant expansion of T helper 1 (Th1)-polarized Teffs and regulatory T cells (Tregs). The cHL Th1 Tregs expressed little or no PD-1, whereas the Th1 Teffs were PD-1+ The differential PD-1 expression and likely functional Th1-polarized CD4+ Tregs and exhausted Teffs may represent complementary mechanisms of immunosuppression in cHL.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29880615 PMCID: PMC6107878 DOI: 10.1182/blood-2018-04-843714
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113